Valuation : Ironwood Pharmaceuticals, Inc.

Market Cap 67Cr 58Cr 55Cr 50Cr 94Cr 6.44TCr 94Cr 653.24Cr 251.2Cr 3.28TCr 253.19Cr 247.64Cr 10TCr P/E 2026 *
3.34x
P/E 2027 * 3.1x
Enterprise Value 67Cr 58Cr 55Cr 50Cr 94Cr 6.44TCr 94Cr 653.24Cr 251.2Cr 3.28TCr 253.19Cr 247.64Cr 10TCr EV / Sales 2026 *
1.43x
EV / Sales 2027 * 1.36x
Free-Float
96.76%
Yield 2026 *
-
Yield 2027 * -
1 day+2.77%
1 week-4.23%
Current month-4.00%
1 month-5.12%
3 months+12.40%
6 months+10.87%
Current year+21.07%
1 week 3.94
Extreme 3.94
4.27
1 month 3.94
Extreme 3.94
4.49
Current year 2.95
Extreme 2.95
5.78
1 year 1.25
Extreme 1.25
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 12/03/2021
Director of Finance/CFO 44 15/05/2026
Chief Tech/Sci/R&D Officer - 20/07/2026
Director TitleAgeSince
Director/Board Member 68 04/06/2021
Chairman 61 01/04/2019
Director/Board Member 56 01/04/2019
Date Insider Type Main position Quantity % Market Cap. Importance
20/07/26 Free

Chief Technology Officer

1,37,036 0.0832%
07/07/26 Sell

Chief Financial Officer

-1,27,890 0.0777%
19/05/26 Free

Chief Financial Officer

25,000 0.0153%
Change 5-day change 1-year change 3-year change Capi.($)
+2.77%-4.23%+229.03%-50.61% 67Cr
-0.54%-4.26%+69.03%+32.53% 36TCr
-0.15%-3.24%+21.83%-20.33% 6.63TCr
+0.19%-2.71%+38.27%+185.87% 1.22TCr
-0.66%-8.82%-11.70%-16.24% 747.11Cr
-4.80%-8.31%-28.14%-8.74% 463.88Cr
+0.63%-2.46%-33.22%+4.34% 441.87Cr
-1.24%-6.98%-34.91%-13.14% 285.73Cr
-0.12%-4.34%-10.76%+39.83% 242.1Cr
-1.84%-5.00%-28.35%-23.61% 190.2Cr
Average -0.58%-4.57%+21.11%+12.99% 4.58TCr
Weighted average by Cap. -0.50%-4.15%+56.85%+26.86%

Financials

2026 *2027 *
Net sales 47Cr 41Cr 38Cr 35Cr 65Cr 4.5TCr 66Cr 456.79Cr 175.66Cr 2.29TCr 177.05Cr 173.17Cr 7.24TCr 49Cr 43Cr 40Cr 37Cr 69Cr 4.72TCr 69Cr 478.7Cr 184.08Cr 2.4TCr 185.55Cr 181.47Cr 7.59TCr
Net income 20Cr 18Cr 17Cr 15Cr 28Cr 1.94TCr 28Cr 196.95Cr 76Cr 987.96Cr 76Cr 75Cr 3.12TCr 22Cr 19Cr 18Cr 16Cr 31Cr 2.1TCr 31Cr 213.04Cr 82Cr 1.07TCr 83Cr 81Cr 3.38TCr
Net Debt - -
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
11/26/11 $4.080 +2.77% 12,49,559
10/26/10 $3.970 -2.46% 11,74,323
09/26/09 $4.070 -2.40% 14,77,426
08/26/08 $4.170 -2.11% 22,75,814
04/26/04 $4.260 -0.70% 8,29,290
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.080USD
Average target price
6.100USD
Spread / Average Target
+49.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IRWD Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!